eFFECTOR Therapeutics, Inc.

NASDAQ:EFTR

$0.0002 USD

$0.0 (-200.0%)

Volume
2.89K
Average Volume
34.54K
Market Capitalization
$941
P/E Ratio
0.00
Dividend Yield
0.00%
Price Target
$5.50
Year High
$17.75
Year Low
$0.00
Payout Ratio
$0.00
Current Ratio
$1.03

Industry, Sector & symbol

Stock Exchange NASDAQ Capital Market
CEO Mr. Craig R. Jalbert CIRA
Industry Biotechnology
Sector Healthcare
Current Symbol EFTR
CUSIP 28202V108
CIK 0001828522
Web https://effector.com
Phone 858 925 8215
Currency USD
Employees 14
Country US

Liquidity

Debt-to-Equity Ratio 24.42
Payout Ratio 0.00
Current Ratio 1.03
Quick Ratio 1.03
Cash Ratio 0.61

Sales & Book Value

Annual Sales $-
Price / Sales 0.01
Cash Flow -7.17
Price / Cash Flow 0.00
Price / Book 0.00

Price Target and Rating

Average Stock Price Forecast $5.50
High Stock Price Forecast $10.00
Low Stock Price Forecast $1.00
Forecast Upside/Downside -100.00%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 2 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-16.37
Trailing P/E Ratio 0.00
PEG Ratio 0.00
P/E Growth 0.00
Net Income $-35.81M
Net Margin -21376.54%
Pretax Margin -21376.54%
Return on Equity 2178.33%
Return on Assets -127.64%

Financials Score

AltmanZ Score -13.63
Piotroski Score 2.00
Working Capital 681K
Total Assets 27.13M
Ebit -32.49M
Market Cap 941
Total Liabilities 26.3M

Poll Results

About eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California. ...

3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off

2024-07-15 09:00:51

As the stock market hits new highs in July, investors are riding a wave of optimism, closely tracking climbing indexes. Yet, beneath this bullish surface, some publicly traded companies are becoming bankruptcy risk stocks as they're grappling with the stark reality of financial distress.

eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

2024-06-24 07:00:00

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a delisting of its securities and expects its securities to be delisted in the near term.

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

2024-05-20 08:30:00

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at DFCI, and an Associate Professor of Medicine at Harvard Medical School.

EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024

2024-05-09 22:56:17

eFFECTOR Therapeutics (NASDAQ: EFTR ) just reported results for the first quarter of 2024. eFFECTOR Therapeutics reported earnings per share of -$2.16.

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

2024-05-09 16:01:00

Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif.

Frequently Asked Questions

What is the current eFFECTOR Therapeutics, Inc. (EFTR) stock price?

eFFECTOR Therapeutics, Inc.(NASDAQ:EFTR) stock price is $0.0002 in the last trading session. During the trading session, EFTR stock reached the peak price of $4 while $1.0E was the lowest point it dropped to. The percentage change in EFTR stock occurred in the recent session was -200.0% while the dollar amount for the price change in EFTR stock was $0.0.

EFTR's industry and sector of operation?

The NASDAQ listed EFTR is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of EFTR?

Mr. Craig R. Jalbert CIRA | Chief Executive Officer, President, Treasurer &Secretary, and Director
Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board
|
|

How many employees does EFTR have?

Number of EFTR employees currently stands at 14. EFTR operates from 142 North Cedros Avenue, Solana Beach, CA 92075, US.

Link for EFTR official website?

Official Website of EFTR is: https://effector.com

How do I contact EFTR?

EFTR could be contacted at phone #858 925 8215 and can also be accessed through its website. EFTR operates from 142 North Cedros Avenue, Solana Beach, CA 92075, US.

How many shares of EFTR are traded daily?

The average number of EFTR shares traded daily for last 3 months was 34.54K.

What is the market cap of EFTR currently?

The market value of EFTR currently stands at $941 with its latest stock price at $0.0002